Anti-CEP Antibody, clone Das-1 (7E12H12)

32160702

NA.41

The monoclonal antibody (mAb) Das-1 was originally desiganted as clone 7E12H12 and was thought to target a 40 kDa colon-specific tropomyosin (TM) isoform or a TM-related protein. It was later found that this clone specifically immunoprecipitated a high molecular weight chaperone protein that targets tropomyosin 5 (TM5) in human colon epithelial cells and subsequently named Colon Epithelial Protein (CEP). The Das-1 target is a glycoprotein with variable apparent sizes depending on the level of glycosylation. The target glycoprotein immunoprecipitated from the plasma membrane of DLD-1 colon cancer cells appears with an apparent molecular size of 185 kDa, while the target isolated from LS-180 colon cancer cells migrates with a size range extends to greater than 200 kDa. Das-1/CEP immunoreactivity is reported to be associated with Barrett′s metaplasia, Barrett′s adenocarcinoma, as well as with gastric adenocarcinomas and carcinoma-associated intestinal metaplasia, but no reactivity has been found in normal esophageal, gastric or small intestinal mucosa. When tested by ELISA and imunoblotting against recombinant human tropomyosins isoforms 1-5, none of five hTM isoforms reacted with mAB DAS-1. As determined by immunofluorescence and FACS analyses, CEP/Das-1 immunoreactivity is detected in several colon cancer lines (DLD-1, LS180, T84), but not in the colorectal adenocarcinoma cell line HT-29. CEP/Das-1 immunoreactivity is not detected among non-colonic epithelial cell lines (293-T, HeLa, pancreatic cancer) or hematopoietic lines (K562, KGI, Daudi).

Clone 7E12H12 (mAb DAS-1) specifically reacts with Colon Epithelial Protein (CEP), but not human tropomyosins isoforms (hTM1-5). CEP/Das-1 immunoreactivity is detected in several colon cancer lines (DLD-1, LS180, T84), but not in the colorectal adenocarcinoma cell line HT-29. CEP/Das-1 immunoreactivity is not detected among non-colonic epithelial cell lines (293-T, HeLa, HUVEC, pancreatic cancer) or hematopoietic lines (K562, KGI, Daudi).

Human colonic protein extract.

Anti-CEP Antibody, clone Das-1 (7E12H12) is an antibody against CEP for use in Immunohistochemistry (Paraffin), Western Blotting, Immunoprecipitation, ELISA, Dot Blot.
Western Blotting Analysis: Prior to the production of Cat. No. MABC530 by ion-exchange chromatography, the CEP immunoreactivity of the ascites was determined by Western blotting against ulcerative colitis (UC) tissue homogenates, LS-180 colon adenocarcinoma cell lysates, LS180 culture supernatant, and purified CEP (Courtesy of Dr. Kiron M. Das, UMDNJ-Robert Wood Johnson Medical School, New Jersey).

Western Blotting Analysis: A representative lot detected elevated CEP (colon epithial specific protein) levels among intraductal papillary mucinous neoplasm (IPMN) patients samples with high-risk/malignant lesions (Das, K.K., et al. (2014). Gut. 63(10):1626-1634).

Western Blotting Analysis: A representative lot detected CEP in colon adenocarcinoma cell line LS180 and in isolated colon epithelial cells, as well as in LS-180 culture supernatant, but not in normal jejunal epithelial cells (Kesari, K.V., et al. (1999). Clin. Exp. Immunol. 118(2):219-227).

Immunoprecipitation Analysis: A representative lot co-immuoprecipitated tropomyosin 5 with CEP from the culture supernatant of human adenocarcinoma cell line LS180 (Kesari, K.V., et al. (1999). Clin. Exp. Immunol. 118(2):219-227).

ELISA Analysis: A representative lot was used as the capture antibody in combination with the isotype switched mAb Das-1 IgG as the detection antibody using purified CEP and cyst fluid samples from Intraductal papillary mucinous neoplasm (IPMN) patients (Das, K.K., et al. (2014). Gut. 63(10):1626-1634).

Immunohistochemistry Analysis: A representative lot detected significantly higher CEP (colon epithial specific protein) immunoreactivity among intraductal papillary mucinous neoplasm (IPMN) patients samples with high-risk/malignant lesions (Das, K.K., et al. (2014). Gut. 63(10):1626-1634).

Immunohistochemistry Analysis: Representative lots detected CEP (colon epithial specific protein) immunoreactivity by both fluorescent and non-fluorescent immunhistochemistry in colonic, but not small intestinal, enterocytes using both frozen and formalin-fixed, paraffin-embedded tissue sections (Moriichi, K., et al. (2009). Int. J. Cancer. 124(6):1263-1269; Piazuelo, M.B., et al. (2004). Mod. Pathol. 17(1):62-74; MIrza, Z.K., et al. (2003). Gut. 52(6):807-812; Glickman, (2001). J.N., et al. Am J Surg Pathol. 25(1):87-94; Griffel, L.H., et al. (2000). Dig. Dis. Sci. 45(1):40-48; Hamilton, M.I., et al. (1995). Clin. Exp. Immunol. 99(3):404-411; Halstensen, T. S., et al. (1993). Gut. 34(5):650-657; Das, K.M., et al. (1987). J. Immunol. Vol. 139(1):77-84).

Dot Blot Analysis: A representative lot detected CEP immunoreactivity in colon protein extracts (Hamilton, M.I., et al. (1995). Clin. Exp. Immunol. 99(3):404-411).

Evaluated by Immunohistochemistry in human colon tissue.

Immunohistochemistry Analysis: A 1:1,000 dilution of this antibody detected CEP in human colon tissue.

Purified by Ion-Exchange Chromatography
Format: Purified

Concentration: Please refer to lot specific datasheet.

100

mouse

affinity purified immunoglobulin

primary antibodies

7E12H12, monoclonal

human

ELISA: suitable
dot blot: suitable
immunohistochemistry: suitable (paraffin)
immunoprecipitation (IP): suitable
western blot: suitable

IgMκ

wet ice

>200 kDa observed. Variable depending on levels of glycosylation.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

10 - Combustible liquids

WGK 2